España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Cybin
CYBN
AMEX
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
Get Report
Comment
Cybin (CYBN) Forecast
News
Earnings
Cybin (CYBN) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Cybin (AMEX:CYBN) Stock
Cybin Stock (AMEX: CYBN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, January 15, 2025
Cybin Announced Partnership With Segal Trials...
Benzinga Newsdesk
Monday, January 13, 2025
Cybin Highlights 2024 Progress, Launches Phas...
Benzinga Newsdesk
Tuesday, December 10, 2024
Cybin Highlights 12-Month Efficacy Results Fr...
Benzinga Newsdesk
Tuesday, November 19, 2024
Canaccord Genuity Maintains Buy on Cybin, Mai...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Cybin, ...
Benzinga Newsdesk
Monday, November 18, 2024
HC Wainwright & Co. Reiterates Buy on Cybin, ...
Benzinga Newsdesk
Thursday, November 14, 2024
Canaccord Genuity Maintains Buy on Cybin, Low...
Benzinga Newsdesk
Wednesday, November 13, 2024
Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression
Franca Quarneti
Thursday, October 24, 2024
EXCLUSIVE: Neuropsychiatry-Focused Cybin Secures First US Composition of Matter Patent For Preclinical CYB005 Phenethylamines Program
Vandana Singh
EXCLUSIVE: Cybin Tells Benzinga 'The Company ...
Benzinga Newsdesk
EXCLUSIVE: Cybin Tells Benzinga Co. Announces...
Benzinga Newsdesk
Monday, September 23, 2024
'DEA Calls For Massive Increases In Psilocybi...
Benzinga Newsdesk
Canaccord Genuity Maintains Buy on Cybin, Low...
Benzinga Newsdesk
Thursday, September 19, 2024
Cybin Provides Corporate Update On Upcoming C...
Benzinga Newsdesk
Friday, September 06, 2024
Leadership Shake-Ups In Cannabis And Psychedelics: Maryland's Cannabis Chief Resigns, Costly Legal Battle In MA Drags On & More
Jelena Martinovic
Friday, August 23, 2024
HC Wainwright & Co. Reiterates Buy on Cybin, ...
Benzinga Newsdesk
Tuesday, August 13, 2024
Cybin Completes FDA Type B Initial Breakthrou...
Benzinga Newsdesk
Cybin Continues To Expect To Commence Phase 3...
Benzinga Newsdesk
Thursday, August 08, 2024
Cybin Q1 Net Loss C$15M Same As Last Year; Ca...
Benzinga Newsdesk
Wednesday, July 31, 2024
Cantor Fitzgerald Reiterates Overweight on Cy...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Cybin, ...
Benzinga Newsdesk
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
Javier Hasse
Tuesday, July 16, 2024
'MDMA Therapy Gets Support From Prominent Res...
Benzinga Newsdesk
Wednesday, June 26, 2024
Biopharma Co. Cybin Reports $78M Loss Amid Accelerating Expansion In Psychedelic Therapies, Drug Development
Patricio Liddle
Cybin Q4 Net Loss C$21M Vs. C$14M YoY, Cash T...
Benzinga Newsdesk
Friday, June 21, 2024
Cantor Fitzgerald Reiterates Overweight on Cy...
Benzinga Newsdesk
Tuesday, June 18, 2024
Latest Executive Cannabis Changes You Should Know About: Curaleaf, Planet 13 Elect Directors And More
Jelena Martinovic
Wednesday, June 12, 2024
'Oregon's First-In-Nation Psilocybin Industry...
Benzinga Newsdesk
Wednesday, June 05, 2024
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
Aaron Bry
Shares of psychedelics companies are trading ...
Benzinga Newsdesk
Thursday, May 16, 2024
HC Wainwright & Co. Reiterates Buy on Cybin, ...
Benzinga Newsdesk
Thursday, May 09, 2024
Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon
Nina Zdinjak
Tuesday, May 07, 2024
"FDA Expert Committee Will Review MDMA-Assist...
Benzinga Newsdesk
Monday, May 06, 2024
Cybin Provides Corporate Update And Highlight...
Benzinga Newsdesk
Tuesday, April 16, 2024
Cybin Announces Grant Of Additional US Patent...
Benzinga Newsdesk
Saturday, March 30, 2024
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
Lara Goldstein
Wednesday, March 20, 2024
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
Lara Goldstein
Friday, March 15, 2024
Cybin Says It Initiated Phase 2 Proof-of-Conc...
Benzinga Newsdesk
Thursday, March 14, 2024
Reported Earlier, 'Indiana Lawmakers Send Psi...
Benzinga Newsdesk
Cybin Announces End-of-Phase 2 Meeting with F...
Benzinga Newsdesk
Wednesday, March 13, 2024
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement
Lara Goldstein
HC Wainwright & Co. Maintains Buy on Cybin, M...
Benzinga Newsdesk
Cybin Receives FDA Breakthrough Therapy Desig...
Benzinga Newsdesk
Monday, March 04, 2024
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Lara Goldstein
Friday, February 16, 2024
Cybin Inc. Q3 Earnings: Clinical Advances Amid Financial Loss
The Dales Report
Thursday, February 15, 2024
HC Wainwright & Co. Reiterates Buy on Cybin, ...
Benzinga Newsdesk
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
Lara Goldstein
Wednesday, February 14, 2024
Cybin Says Net Loss Was C$30.3 Million For Q3...
Benzinga Newsdesk
Monday, February 12, 2024
'FDA Grants Priority Review Of MDMA-Assisted ...
Benzinga Newsdesk
Wednesday, February 07, 2024
Cybin Reveals Grant Of Two Additional Patents...
Benzinga Newsdesk
Show More
